Castle Biosciences (CSTL) EBITDA Margin (2018 - 2026)
Castle Biosciences (CSTL) posted EBITDA Margin of 2.96% for Q2 2026, up 86.52% sequentially from 22.0% in Q1 2026, and up 197.0% YoY from 1.0% in Q2 2025.
Castle Biosciences (CSTL) EBITDA Margin (2018 - 2026) Analysis & Trends
Castle Biosciences has reported EBITDA Margin for 9 years, with the latest figure at 2.96% in Q2 2026.
- Quarterly EBITDA Margin rose 197.0% year-over-year to 2.96% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 8.99% (down 233.0% YoY) and the FY2025 annual result came in at 12.44%, down 1505.0% from the prior year.
- EBITDA Margin advanced to 2.96% in Q2 2026 per CSTL's latest filing, from 22.0% in the prior quarter.
- Over five years, EBITDA Margin peaked at 5.92% in Q3 2024 and troughed at 91.3% in Q1 2022.
- A 5-year average of 23.73% and a median of 9.98% in 2022 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2024: EBITDA Margin slumped 7252 bps in 2022, then jumped 6749 bps in 2024.
- Over 5 years, EBITDA Margin stood at 59.55% in 2022, then jumped by 86 bps to 8.56% in 2023, then surged by 155 bps to 4.69% in 2024, then sank by 194 bps to 4.4% in 2025, then jumped by 33 bps to 2.96% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 2.96%, 22.0%, and 4.4% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 17.40% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 17.99% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 34.98% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 21.74% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 11.58% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -13.42% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 21.14% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 31.97% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 15.08% |
| 10 | Castle Biosciences | 926.56 Mn | 659.75 Mn | 79.85 Mn | -2.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.96% |
| Mar 31, 2026 | -22.00% |
| Dec 31, 2025 | -4.40% |
| Sep 30, 2025 | -8.19% |
| Jun 30, 2025 | -4.93% |
| Mar 31, 2025 | -31.74% |
| Dec 31, 2024 | 4.69% |
| Sep 30, 2024 | 5.92% |
| Jun 30, 2024 | 5.76% |
| Mar 31, 2024 | -7.50% |
| Dec 31, 2023 | -8.56% |
| Sep 30, 2023 | -15.68% |
| Jun 30, 2023 | -42.20% |
| Mar 31, 2023 | -74.99% |
| Dec 31, 2022 | -59.55% |
| Sep 30, 2022 | -58.19% |
| Jun 30, 2022 | -11.40% |
| Mar 31, 2022 | -91.30% |
| Dec 31, 2021 | -60.59% |
| Sep 30, 2021 | -50.33% |